Febuxostat

A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.

Also Known As:

2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid; TEI 6720; TEI-6720; Uloric; 6720, TEI; TEI6720; 5-Thiazolecarboxylic acid, 2-(3-cyano-4-(2-methylpropoxy)phenyl)-4-methyl-

Networked: 693 relevant articles (113 outcomes, 229 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Singh, Jasvinder A: 22 articles (01/2022 - 01/2010)
2.	Hosoya, Tatsuo: 14 articles (01/2022 - 06/2011)
3.	Hunt, Barbara: 14 articles (01/2022 - 11/2008)
4.	Becker, Michael A: 13 articles (01/2022 - 03/2005)
5.	Gunawardhana, Lhanoo: 12 articles (01/2022 - 01/2011)
6.	MacDonald, Patricia A: 11 articles (12/2017 - 03/2005)
7.	Cleveland, John D: 10 articles (01/2020 - 01/2018)
8.	Dalbeth, Nicola: 9 articles (07/2022 - 06/2009)
9.	Terkeltaub, Robert: 9 articles (07/2022 - 04/2009)
10.	Whelton, Andrew: 9 articles (01/2022 - 01/2011)

Related Diseases

1.	Gout 03/01/2015 - "In open-label extension studies, 3-5 years' treatment with febuxostat maintained a target sUA level of <6.0 mg/dL in most patients; sustained reduction in sUA level was associated with near elimination of gout flares and improved tophus status. " 09/01/2018 - "Febuxostat is potent and well-tolerated in the management of chronic gout. " 03/01/2016 - "Febuxostat is a suitable pharmacological option for first line treatment of gout, given its established efficacy and safety, documented in a high number of clinical studies and in daily practice." 01/01/2022 - "This is the first reported example and he has shown no side effect till now, while his gout improved of a successful desensitization protocol using a solid preparation of diluted febuxostat given as pills." 01/01/2019 - "Equivalent doses of febuxostat XR and IR had similar treatment effects on serum UA level end points; however, a significantly greater proportion of patients achieved a serum UA level of <5.0 mg/dl with XR 40 mg versus IR 40 mg. Similar proportions of patients experienced ≥1 gout flare across treatment groups. "
2.	Hyperuricemia 03/01/2022 - "Although febuxostat did not show a positive effect overall, it significantly improved renal function (i.e., eGFR) in a subgroup of CKD patients with hyperuricemia (MD [95% CI]: 0.85 [0.02; 1.67], P = 0.045). " 09/14/1993 - "These results suggest that TEI-6720 may be useful for the treatment of hyperuricemia." 12/01/2015 - "Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial." 01/01/2017 - "Febuxostat has currently played pivotal role in the treatment of hyperuricemia, but there is little comprehensive information for the determinants of individual difference in efficacy of febuxostat. " 01/01/2022 - "Febuxostat treatment did not alter endothelial function assessed by FMD during a 2-year study period in patients with asymptomatic hyperuricemia."
3.	Chronic Renal Insufficiency 09/01/2018 - "Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD." 01/01/2020 - "The safety and efficacy of febuxostat in patients with stage 4-5 chronic kidney disease (CKD) are still unclear owing to a lack of studies in these patients. " 03/01/2018 - "To investigate the efficacy of febuxostat in hyperuricemic patients with chronic kidney disease (CKD), relevant randomized clinical trials (RCTs) were analyzed. " 10/01/2017 - "We aimed to study the safety and efficacy of febuxostat for stage 4/5 chronic kidney disease. " 05/01/2023 - "Effects of febuxostat on delaying chronic kidney disease progression: a randomized trial in China."
4.	Hypertension (High Blood Pressure) 11/04/2017 - "This study suggests that febuxostat may lower BP in hyperuricemic patients with hypertension and normal renal function; further studies should be conducted to confirm this finding. " 11/04/2017 - "Effect of Febuxostat on Ambulatory Blood Pressure in Subjects With Hyperuricemia and Hypertension: A Phase 2 Randomized Placebo-Controlled Study." 01/01/2013 - "To resolve this controversy, in this study we used the newer and more effective XO inhibitor febuxostat, and hypothesized that a more complete XO blockade might impair hypertension development and its end-organ consequences. " 08/01/2016 - "To explore the possible involvement of XO-derived oxidative stress in the pathophysiology of vascular dysfunction, by use of a selective XO inhibitor, febuxostat, we investigated the impact of pharmacological inhibition of XO on hypertension and vascular endothelial dysfunction in spontaneously hypertensive rats (SHRs). " 12/01/2015 - "These results support the hypothesis that febuxostat might not only reduce serum UA levels but also suppress RAAS and improve renal function in hyperuricemic patients with hypertension, possibly leading to prevention of CVD."
5.	Inflammation (Inflammations) 01/01/2013 - "Thus, it may be possible that the inhibition of this enzymatic pathway by febuxostat would be beneficial for the vascular inflammation. " 10/01/2023 - "Here, we investigated whether inhibition of inflammation using febuxostat lowered the risk of cardiovascular events. " 01/01/2022 - "Febuxostat alleviates AR by inhibiting inflammation and monocyte adhesion in human nasal epithelial cells through the regulation of KLF6." 07/01/2019 - "The effects of febuxostat on atrial electrical and structural remodeling, markers of inflammation and oxidative stress, and signaling pathways involved in the left atrium were examined. " 01/01/2022 - "In the vivo experiments, we observed that febuxostat ameliorated the increased sneezing times, the number of nose scratching episodes, and elevated HE pathological scores as well as alleviated the inflammation in nasal mucous tissues of AR mice. "

Related Drugs and Biologics

1.	Allopurinol (Remid)
2.	Uric Acid (Urate)
3.	Xanthine Oxidase
4.	purine
5.	Benzbromarone
6.	Creatinine
7.	HLA-B Antigens (HLA-B)
8.	Febuxostat
9.	Xanthine Dehydrogenase
10.	Insulin (Novolin)

Related Therapies and Procedures

1.	Therapeutics
2.	Renal Dialysis (Hemodialysis)
3.	Percutaneous Coronary Intervention
4.	Ligation
5.	Intra-Articular Injections